What is AlloSource?
Founded in 1994 and headquartered in Colorado, AlloSource operates at the intersection of biotechnology and clinical application. As a nonprofit organization, its primary mandate is to push the boundaries of allogeneic tissue science, ensuring that high-quality, safe, and effective biological grafts are available for surgical procedures. By maintaining a rigorous focus on tissue processing and distribution, the company has established itself as a cornerstone in the medical supply chain, supporting complex surgical interventions that rely on advanced cellular and tissue-based therapies. Their market position is defined by a commitment to patient outcomes rather than traditional profit-driven metrics, allowing for sustained investment in research and development.
How much funding has AlloSource raised?
AlloSource has raised a total of $5M across 1 funding round:
Debt
$5M
Debt (2020): $5M with participation from PPP
Key Investors in AlloSource
PPP
Public-Private Partnership
What's next for AlloSource?
With the recent influx of capital, AlloSource is well-positioned to scale its operational capabilities and deepen its research initiatives. The organization is expected to leverage this financial backing to enhance its processing infrastructure and expand its reach within the surgical community. As the demand for regenerative medicine continues to grow, AlloSource will likely focus on optimizing its supply chain efficiency and exploring new frontiers in allogeneic cell therapy. This strategic deployment of resources will be pivotal in maintaining their competitive edge and ensuring that surgeons have consistent access to the innovative biological solutions necessary for modern patient care.
See full AlloSource company page
